News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
534,466 Results
Type
Article (21527)
Company Profile (223)
Press Release (512798)
Multimedia
Podcasts (243)
Webinars (21)
Section
Business (182923)
Career Advice (1062)
Deals (28305)
Drug Delivery (114)
Drug Development (61247)
Employer Resources (145)
FDA (11034)
Job Trends (10436)
News (263186)
Policy (21010)
Tag
2027 BioMidwest Elite (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (4)
Academia (920)
Academic (1)
Accelerated approval (39)
ADA (27)
Adcomms (18)
Allergies (119)
Alliances (37454)
ALS (145)
Alzheimer's disease (1227)
Antibody-drug conjugate (ADC) (372)
Approvals (11392)
Artificial intelligence (548)
ASCO (213)
Autoimmune disease (258)
Automation (39)
Bankruptcy (301)
Best Places to Work (7570)
BIO (81)
Biologics (1)
BIOSECURE Act (17)
Biosimilars (156)
BioSpace Insights (232)
Biotechnology (139)
Bladder cancer (150)
Brain cancer (40)
Breast cancer (562)
Cancer (4271)
Cardiovascular disease (326)
Career advice (928)
Career pathing (41)
CAR-T (243)
CDC (31)
Celiac Disease (2)
Cell therapy (706)
Cervical cancer (36)
Clinical research (53403)
Collaboration (1602)
Commercialization (7)
Company closure (7)
Compensation (1474)
Complete response letters (57)
COVID-19 (1900)
CRISPR (96)
C-suite (951)
Cystic fibrosis (105)
Data (6132)
Decentralized trials (2)
Denatured (99)
Depression (139)
Dermatology (63)
Diabetes (413)
Diagnostics (4666)
Digital health (41)
Diversity (12)
Diversity, equity & inclusion (41)
Drug discovery (272)
Drug pricing (94)
Drug shortages (14)
Duchenne muscular dystrophy (226)
Earnings (76483)
Editorial (56)
Employer branding (22)
Employer resources (120)
Events (95169)
Executive appointments (839)
FDA (13829)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (22)
Frontotemporal dementia (26)
Funding (1326)
Gene editing (193)
Generative AI (49)
Gene therapy (554)
GLP-1 (689)
Government (1895)
Grass and pollen (3)
Guidances (294)
Healthcare (10312)
Hematology (109)
HIV (60)
Huntington's disease (45)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (87)
Immunology and inflammation (210)
Immuno-oncology (79)
Indications (165)
Infectious disease (2134)
Inflammatory bowel disease (148)
Inflation Reduction Act (13)
Influenza (99)
Intellectual property (274)
Interviews (169)
IPO (13230)
IRA (27)
Job creations (3006)
Job search strategy (811)
JPM (61)
Kidney cancer (16)
Labor market (125)
Layoffs (372)
Leadership (25)
Legal (5871)
Licensing (9)
Liver cancer (62)
Longevity (26)
Lung cancer (603)
Lymphoma (278)
Machine learning (44)
Management (35)
Manufacturing (833)
Marketing (9)
MASH (161)
Medical device (9084)
Medtech (9233)
Mergers & acquisitions (16153)
Metabolic disorders (1072)
mRNA (217)
Multiple sclerosis (120)
NASH (12)
Neurodegenerative disease (325)
Neuropsychiatric disorders (66)
Neuroscience (2316)
Neurotech (1)
NextGen: Class of 2026 (3981)
Non-profit (1071)
Now hiring (82)
Obesity (450)
Opinion (210)
Ovarian cancer (173)
Pain (189)
Pancreatic cancer (228)
Parkinson's disease (236)
Partnered (34)
Patents (524)
Patient recruitment (564)
Peanut (35)
People (45911)
Pharmaceutical (44)
Pharmacy benefit managers (16)
Phase 1 (17365)
Phase 2 (24079)
Phase 3 (16723)
Pipeline (7898)
Policy (233)
Postmarket research (1669)
Preclinical (7308)
Press Release (47)
Prostate cancer (209)
Psychedelics (60)
Radiopharmaceuticals (240)
Rare diseases (865)
Real estate (3913)
Recruiting (55)
Regulatory (17100)
Reports (78)
Research institute (965)
Resumes & cover letters (153)
Rett syndrome (44)
RNA editing (22)
RSV (57)
Schizophrenia (121)
Series A (258)
Series B (190)
Service/supplier (6)
Sickle cell disease (83)
Special edition (32)
Spinal muscular atrophy (106)
Sponsored (29)
Startups (2882)
State (1)
Stomach cancer (7)
Supply chain (79)
Tariffs (33)
The Weekly (141)
Vaccines (826)
Venture capital (122)
Weight loss (259)
Women's health (102)
Worklife (19)
Date
Today (2)
Last 7 days (512)
Last 30 days (1829)
Last 365 days (21835)
2026 (13941)
2025 (21829)
2024 (25947)
2023 (29615)
2022 (38617)
2021 (41004)
2020 (36502)
2019 (26109)
2018 (19578)
2017 (21981)
2016 (21355)
2015 (26993)
2014 (23783)
2013 (19818)
2012 (21881)
2011 (22022)
2010 (21652)
Location
Africa (514)
Alabama (78)
Alaska (2)
Arizona (310)
Arkansas (12)
Asia (24386)
Australia (3107)
California (12654)
Canada (3285)
China (826)
Colorado (502)
Connecticut (441)
Delaware (259)
Europe (37592)
Florida (1830)
Georgia (385)
Hawaii (4)
Idaho (51)
Illinois (813)
India (70)
Indiana (343)
Iowa (18)
Japan (435)
Kansas (115)
Kentucky (34)
Louisiana (32)
Maine (27)
Maryland (1278)
Massachusetts (8495)
Michigan (319)
Minnesota (630)
Mississippi (5)
Missouri (91)
Montana (21)
Nebraska (14)
Nevada (144)
New Hampshire (70)
New Jersey (2756)
New Mexico (21)
New York (2963)
North Carolina (1364)
North Dakota (5)
Northern California (6351)
Ohio (329)
Oklahoma (16)
Oregon (21)
Pennsylvania (2369)
Puerto Rico (23)
Rhode Island (35)
South America (681)
South Carolina (78)
South Dakota (1)
Southern California (5143)
Tennessee (128)
Texas (2088)
United States (41257)
Utah (407)
Vermont (1)
Virginia (171)
Washington D.C. (52)
Washington State (968)
West Virginia (2)
Wisconsin (81)
534,466 Results for "treos bio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
TREOS Bio Appoints Sunjeet Sawhney as Chief Executive Officer
May 28, 2026
·
3 min read
Press Releases
Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer
July 2, 2026
·
3 min read
Press Releases
TREOS Bio Presents New PEPI Technology Data at EACR 2026, Including Six-Year Cancer-Free Outcome in MSS Metastatic Colorectal Cancer (mCRC)
June 9, 2026
·
5 min read
Press Releases
TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances
November 6, 2025
·
3 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Press Releases
TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
August 28, 2025
·
3 min read
Press Releases
BIO 2026 – Cytomos showcases groundbreaking new digital platform AuraCyt®, which enables earlier, smarter bioprocessing decisions
At this year’s annual meeting of the Bio International Convention (BIO) in San Diego, CA, TechBio company Cytomos (www.cytomos.com) is showcasing their flagship cell analytic intelligence platform AuraCyt® – together with its novel benchtop technology Celledonia® – which is set to revolutionise predictive cell analytics.
June 22, 2026
·
1 min read
Genetown
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.
May 8, 2024
·
2 min read
Genetown
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
Treos Bio Limited announced the presentation of results from its phase 2 OBERTO-301 study of the company’s lead product candidate, PolyPEPI1018, in combination with atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 American Society of Clinical Oncology Annual Meeting.
June 3, 2024
·
7 min read
Press Releases
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
July 29, 2026
·
6 min read
1 of 53,447
Next
